MACROGENICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MACROGENICS, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $187.00K.
- MACROGENICS, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $235.00K.
- MACROGENICS, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $617.00K.
- MACROGENICS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $19.64M, a 73.45% decline year-over-year.
- MACROGENICS, INC. stock issued during period, value, new issues for fiscal 2023 was $1.04M, a 4.24% decline from fiscal 2022.
- MACROGENICS, INC. stock issued during period, value, new issues for fiscal 2022 was $1.08M, a 99.08% decline from fiscal 2021.
- MACROGENICS, INC. stock issued during period, value, new issues for fiscal 2021 was $117.82M, a 30.88% decline from fiscal 2020.
- MACROGENICS, INC. stock issued during period, value, new issues for fiscal 2020 was $170.46M, a 43.65% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $1.04M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $187.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $235.00K 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $617.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $1.08M 10-K · filed 2025-03-20 | |
| 2021-12-31 | $117.82M 10-K · filed 2024-03-07 | |
| 2021-09-30 | $19.64M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $98.20M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $170.46M 10-K · filed 2023-03-15 | |
| 2020-09-30 | $73.98M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $96.51M 10-Q · filed 2021-11-02 | |
| 2019-12-31 | $118.66M 10-K · filed 2022-02-24 | |
| 2019-03-31 | $118.66M 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $103.26M 10-K · filed 2021-02-25 | |
| 2018-06-30 | $103.26M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $34.24M 10-K · filed 2020-02-25 | |
| 2015-12-31 | $203.47M 10-K · filed 2018-02-27 | |
| 2014-12-31 | $76.72M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $83.62M 10-K · filed 2016-02-29 | |
| 2011-12-31 | $12.01M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |